Alici E - Search Results

1

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Nahi H, Afram G, Uttervall K, Lockmer S, Tätting L, Gahrton G, Kashif M, Alici E, Stromberg O, Klimkowska M, Lund J. Nahi H, et al. Among authors: alici e. Cancer Med. 2023 Nov;12(22):20736-20744. doi: 10.1002/cam4.6640. Epub 2023 Nov 3. Cancer Med. 2023. PMID: 37921243 Free PMC article.

2

Ex vivo expansion of natural killer cells: a question of function.

Sutlu T, Alici E. Sutlu T, et al. Among authors: alici e. Cytotherapy. 2011 Jul;13(6):767-8. doi: 10.3109/14653249.2011.563295. Epub 2011 Mar 7. Cytotherapy. 2011. PMID: 21375422 No abstract available.

3

Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data.

Martins JP, Santos JM, de Almeida JM, Filipe MA, de Almeida MV, Almeida SC, Água-Doce A, Varela A, Gilljam M, Stellan B, Pohl S, Dittmar K, Lindenmaier W, Alici E, Graça L, Cruz PE, Cruz HJ, Bárcia RN. Martins JP, et al. Among authors: alici e. Stem Cell Res Ther. 2014 Jan 17;5(1):9. doi: 10.1186/scrt398. Stem Cell Res Ther. 2014. PMID: 24438697 Free PMC article.

4

Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.

Alici E, Björkstrand B, Treschow A, Aints A, Smith CI, Gahrton G, Dilber MS. Alici E, et al. Cancer Gene Ther. 2007 Mar;14(3):227-32. doi: 10.1038/sj.cgt.7701006. Epub 2006 Nov 3. Cancer Gene Ther. 2007. PMID: 17082794

5

Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.

Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, Dilber MS. Alici E, et al. Exp Hematol. 2007 Dec;35(12):1839-46. doi: 10.1016/j.exphem.2007.08.006. Exp Hematol. 2007. PMID: 18036444 Free article.

6

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.

Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS. Alici E, et al. Blood. 2008 Mar 15;111(6):3155-62. doi: 10.1182/blood-2007-09-110312. Epub 2008 Jan 11. Blood. 2008. PMID: 18192509 Free article.

7

The prognostic significance of 8p21 deletion in multiple myeloma.

Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. Sutlu T, et al. Among authors: alici e. Br J Haematol. 2009 Jan;144(2):266-8. doi: 10.1111/j.1365-2141.2008.07454.x. Epub 2008 Nov 11. Br J Haematol. 2009. PMID: 19016723 Free article. No abstract available.

8

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.

Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom A, Gahrton G, Nahi H. Paul E, et al. Among authors: alici e. Oncol Rep. 2009 Jul;22(1):137-42. doi: 10.3892/or_00000416. Oncol Rep. 2009. PMID: 19513515

9

Constitutional inv(3) in myelodysplastic syndromes.

Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Gahrton C, et al. Among authors: alici e. Leuk Res. 2010 Dec;34(12):1627-9. doi: 10.1016/j.leukres.2010.05.014. Epub 2010 Jun 9. Leuk Res. 2010. PMID: 20542563

10

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.

Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, Alici E. Sutlu T, et al. Among authors: alici e. Cytotherapy. 2010 Dec;12(8):1044-55. doi: 10.3109/14653249.2010.504770. Epub 2010 Aug 26. Cytotherapy. 2010. PMID: 20795758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page